ECM
RGNX icon

Everence Capital Management’s Regenxbio RGNX Stock Holding History

Everence Capital Management’s Portfolio RGNX Stock Details RGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-11,650
Closed -$122K – 997
2024
Q3 		$122K Buy
11,650
+200
+2% +$2.44K 0.01% 740
2024
Q2 		$176 Hold
11,450
– – 0.01% 701
2024
Q1 		$241 Hold
11,450
– – 0.02% 652
2023
Q4 		$206K Hold
11,450
– – 0.01% 696
2023
Q3 		$188 Buy
+11,450
New +$207K 0.01% 683
2021
Q4 		– Sell
-5,140
Closed -$215K – 791
2021
Q3 		$215K Buy
+5,140
New +$185K 0.02% 673
2021
Q1 		– Sell
-5,140
Closed -$233K – 735
2020
Q4 		$233K Buy
+5,140
New +$180K 0.02% 604

Other funds holding RGNX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Everence Capital Management's RGNX Position: Q4 2024 in Review

Everence Capital Management sold out of Regenxbio (RGNX) in Q4 2024, closing a stake of 11,650 shares — an estimated $122K sold.

Everence Capital Management first reported a position in RGNX in Q4 2020 and held it in 7 quarters. The position peaked at $233K in Q4 2020. 177 funds tracked by Wall St. Rank hold RGNX as of Q4 2024.

  • Everence Capital Management reported no remaining Regenxbio position as of Q4 2024 after selling out during the quarter.
  • Everence Capital Management sold 11,650 Regenxbio shares in Q4 2024, an estimated $122K.
  • Everence Capital Management first reported a position in Regenxbio in Q4 2020 and held it in 7 quarters.
  • Everence Capital Management's Regenxbio position peaked at $233K in Q4 2020.
  • 177 funds tracked by Wall St. Rank held Regenxbio as of Q4 2024.

Based on Everence Capital Management's 13F filing for Q4 2024, filed 3 Jan 2025.